Bharat Immunologicals Financial Statements Trends

This module enables investors to look at Bharat Immunologicals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as , but also many exotic indicators such as . This module is a perfect complement to use when analyzing Bharat Immunologicals Valuation or Volatility. It can also complement various Bharat Immunologicals Technical models. Check also analysis of Bharat Immunologicals Correlation with competitors.

Cash and Equivalents Analysis

Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Bharat Immunologicals 
Cash 
 = 
Bank Deposits 
+  
Liquidities 
 = 
152.27 M

About Cash and Equivalents

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually 3 months).
Compare to competition
In accordance with recently published financial statements Bharat Immunologicals Biologicals Corp Ltd has 152.27 M in Cash and Equivalents. This is much higher than that of the sector, and significantly higher than that of Cash and Equivalents industry, The Cash and Equivalents for all stocks is over 1000% lower than the firm.

Bharat Immunologicals Fundamental Drivers Relationships

Bharat Immunologicals Biologicals Corp Ltd is number one stock in price to earning category among related companies. It is rated below average in total debt category among related companies making up about  2,700,532  of Total Debt per Price to Earning.

Peer Comparison

Bharat Immunologicals Price to Earning Comparison
Bharat Immunologicals is currently under evaluation in price to earning category among related companies.

Did you try this?

Run Portfolio Volatility Now
   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
Hide  View All  Next  Launch Portfolio Volatility
Return On Equity(11.52) %
Return On Asset(1.69) %
Profit Margin(4.18) %
Operating Margin(5.13) %
Current Valuation862.5 M
Shares Outstanding43.18 M
Price to Earning65.75 times
Price to Book2.50 times
Price to Sales0.66 times
Revenue1.28 B
Gross Profit119 M
EBITDA(56.51 M)
Net Income(53.46 M)
Cash and Equivalents152.27 M
Cash per Share3.55 times
Total Debt177.56 M
Debt to Equity0.50 times
Current Ratio1.69 times
Book Value Per Share8.21 times
Earnings Per Share(1.24) times
Market Capitalization844.17 M
Z Score2.4